A U.S. federal judge has turned down Ranbaxy Laboratories' request for a temporary restraining order against the FDA after the agency revoked the Indian drugmaker's approvals to make generics of AstraZeneca's ($AZN) blockbuster Nexium and Roche's ($RHHBY) antiviral Valcyte because of its manufacturing shortcomings. The FDA has already granted Dr. Reddy's Laboratories and Endo Health Solutions ($ENDP) permission to manufacture generic Valcyte, and Ranbaxy had hoped to stop that from happening. Endo announced today it was rolling out its product immediately. Story | More | FiercePharma article